医用聚羟基脂肪酸酯（PHA）的生物合成策略及其在人类健康领域的新进展

doi:10.12211/2096-8280.2025-059

合成生物学

• 特约评述 •

医用聚羟基脂肪酸酯（PHA）的生物合成策略及其在人类健康领域的新进展

田英入¹, 黄晓云¹, 刀金威², 李玥昊¹, 徐涛¹, 杨辉¹, 万丹丹¹, 魏岱旭³

^1.曲靖健康医学院，云南曲靖 655100
^2.德宏师范学院德宏生物医药工程研究中心，云南芒市 678400
^3.成都大学临床医学院与附属医院，四川成都 610106

收稿日期:2025-06-12 修回日期:2025-11-04 出版日期:2025-11-10
通讯作者: 刀金威,魏岱旭
作者简介:田英入（1996—），女，硕士研究生。曲靖健康医学院临床学院教师。研究方向为生物材料、合成生物学、组织工程与再生医学、生殖医学、妇产科学、生理学。 E-mail：tianyinrude@163.com
黄晓云（1982—），曲靖健康医学院临床医学院副教授。主要研究小细胞肺癌（NSCLC）的发病机制、治疗药物和智能给药系统等多个领域，目标是识别疾病中的关键分子和通路机制，以开发可行的治疗目标和方法用于临床应用。E-mail:953614419@qq.com
刀金威（1986—），男，博士，德宏师范学院副教授。研究方向为生物材料学、医学组织工程学和病原生物学。 E-mail：daojw15@tsinghua.org.cn
魏岱旭（1986—），男，博士，成都大学临床医学院及附属医院教授、博士生导师、硕士生导师。主要从事聚羟基脂肪酸酯（PHA）及其酮体衍生物（3HB）的生物学效应及综合利用，涉及合成生物学、组织工程与再生医学、医用微纳米器件、智能递药系统、医学美容及化妆品、益生菌外泌体、可降解微塑料毒理、脑科学与抗衰老等领域，曾带领本科生获得2019年和2021年iGEM金奖。 E-mail：weidaixu@cdu.edu.cn
第一联系人：共同第一作者
基金资助:
四川省卫生健康委员会医学科学研究项目(24WSXT106);中国陕西省自然科学基础研究计划项目(2024JC-YBMS-706);自贡医学大数据与人工智能协同创新项目(2023-YGY-1-02);自贡市重点科技计划项目(2022ZCNKY07);自贡市重点科技计划项目(2024-NKY01-01);云南省科学技术厅-云南中医药大学基础研究联合基金(202101AZ070001-102);云南省教育厅科学研究基金项目(2023J1773);云南省科技厅科技计划项目(202401AZ070001-097);曲靖健康医学院校级科学研究基金项目(2025ZD04)

Biosynthetic strategies of medical polyhydroxyalkanoate （PHA） and their new developments for human health

TIAN Yingru¹, HUANG Xiaoyun¹, DAO Jinwei², LI Yuehao¹, XU Tao¹, YANG Hui¹, WAN Dandan¹, WEI Daixu³

^1.Qujing University of Medicine & Health Sciences，Qujing 655100，Yunnan，China
^2.Dehong Biomedical Engineering Research Center，Dehong Normal University，Dehong 678400，Yunnan，China
^3.Chengdu University，Clinical Medical College and Affiliated Hospital，Chengdu 610106，Sichuan，China

Received:2025-06-12 Revised:2025-11-04 Online:2025-11-10
Contact: DAO Jinwei, WEI Daixu

摘要/Abstract

摘要：

聚羟基脂肪酸酯（PHA）是一类具有生物相容性、生物可降解性以及优良材料学性能的生物合成聚酯，在医药领域展现出巨大的应用潜力。然而，产能低限制了PHA的应用。近年来，合成生物学技术的发展为PHA的优化生产提供了新途径。本文综述了PHA作为医用材料的优势，包括单体多样性、可控降解性及优异的生物相容性；探讨了合成生物学技术在PHA生产中的应用，如CRISPR/Cas工具、启动子工程、RBS优化、微生物细胞形态工程、染色体整合技术等策略，这些策略可优化合成途径和提高产量，并且推动工业化制备医用级PHA的进展。我们进一步阐述了医用级PHA近些年在骨修复、皮肤再生、心血管工程等领域取得的显著应用成果。未来，融合多学科创新有望突破PHA的技术壁垒，使其成为生物医用材料领域的核心选项，推动再生医学的发展。

关键词: 聚羟基脂肪酸酯（PHA）, 合成生物学, 生物医用材料, 组织工程, 生物相容性, 可降解性

Abstract:

Polyhydroxyalkanoates (PHA) constitute a versatile class of microbial polyesters that exhibit exceptional biocompatibility, tunable biodegradability, and a broad spectrum of mechanical and chemical properties. These characteristics render PHA highly suitable for diverse biomedical applications, including tissue engineering scaffolds, targeted drug delivery systems, wound dressings, and implantable devices. Notably, the degradation products of PHA—such as 3-hydroxybutyrate—are endogenous metabolites, thereby minimizing immunogenic responses and enhancing long-term biocompatibility compared to conventional synthetic polymers. Recent advances in synthetic biology have significantly enhanced PHA biosynthesis. Metabolic engineering strategies—such as CRISPR/Cas9-mediated genome editing for redirecting carbon flux toward PHA accumulation, CRISPR interference (CRISPRi) for modulating competing pathways, and optimization of promoter and ribosome-binding site (RBS) libraries—have enabled precise control over monomer composition and polymer properties. Additionally, microbial morphological engineering, including FtsZ-targeted cell elongation, has been employed to increase intracellular PHA content to over 90% of cellular dry weight. These developments have facilitated the synthesis of tailored PHA variants, ranging from rigid poly(3-hydroxybutyrate) (PHB) to elastomeric poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P34HB). Medical-grade PHA has demonstrated significant translational potential across multiple therapeutic domains. Injectable porous microspheres composed of poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) (PHBVHHx) have been developed for minimally invasive bone regeneration. Electrospun P34HB scaffolds exhibit concurrent antibacterial and pro-angiogenic activities, accelerating wound healing. PHA-based nanocarriers enable sustained drug release in the context of Alzheimer's disease and systemic lupus erythematosus. Furthermore, virus-mimetic PHA particles have been exploited as adjuvant systems to enhance antigen presentation in tuberculosis and COVID-19 vaccine platforms. Future perspectives emphasize the convergence of synthetic biology, materials science, and clinical translation to fully realize the biomedical potential of PHA. Next-generation industrial biotechnology (NGIB), utilizing halophilic microorganisms for continuous fermentation under open conditions, coupled with advanced downstream purification protocols, is anticipated to enhance the scalability and accessibility of medical-grade PHA. Integration with emerging technologies such as 3D bioprinting and organoid culture systems is expected to expand PHA's utility in complex, patient-specific tissue engineering applications. Collectively, these advances position PHA as a promising platform biomaterial for next-generation regenerative medicine and targeted therapeutic strategies.

Key words: Polyhydroxyalkanoate (PHA), Synthetic biology, Biomedical materials, Tissue engineering, Biocompatibility, Degradability

中图分类号:

TQ323.4

田英入, 黄晓云, 刀金威, 李玥昊, 徐涛, 杨辉, 万丹丹, 魏岱旭. 医用聚羟基脂肪酸酯（PHA）的生物合成策略及其在人类健康领域的新进展[J]. 合成生物学, DOI: 10.12211/2096-8280.2025-059.

TIAN Yingru, HUANG Xiaoyun, DAO Jinwei, LI Yuehao, XU Tao, YANG Hui, WAN Dandan, WEI Daixu. Biosynthetic strategies of medical polyhydroxyalkanoate （PHA） and their new developments for human health[J]. Synthetic Biology Journal, DOI: 10.12211/2096-8280.2025-059.

图/表 3

参考文献 90

[1]	ZHANG S Q, YUAN H Z, MA X, et al. Carbon cycle of polyhydroxyalkanoates (CCP): Biosynthesis and biodegradation[J]. Environmental Research, 2025, 269: 120904.
[2]	REN Z W, WANG Z Y, DING Y W, et al. Polyhydroxyalkanoates: the natural biopolyester for future medical innovations[J]. Biomaterials Science, 2023, 11(18): 6013-6034.
[3]	MI C H, QI X Y, DING Y W, et al. Recent advances of medical polyhydroxyalkanoates in musculoskeletal system[J]. Biomaterials Translational, 2023, 4(4): 234-247.
[4]	MI C H, QI X Y, ZHOU Y W, et al. Advances in medical polyesters for vascular tissue engineering[J]. Discover Nano, 2024, 19(1): 125.
[5]	LI H R, ZHOU J, ZHOU Y W, et al. Advances in photocrosslinked natural hydrogel-based microspheres for bone repair[J]. Journal of Polymer Science, 2024, 62(22): 4966-4992.
[6]	HUANG X Y, QI Z D, DAO J W, et al. Current situation and challenges of polyhydroxyalkanoates-derived nanocarriers for cancer therapy[J]. Smart Materials in Medicine, 2024, 5(4): 529-541.
[7]	WEI D X, CHEN Z C. Current situation and challenge of exogenous 3-hydroxybutyrate derived from polyhydroxyalkanoates for elderly health: a review[J]. International Journal of Biological Macromolecules, 2025, 285: 138328.
[8]	XIANG Y, WANG Q Q, LAN X Q, et al. Function and treatment strategies of β-hydroxybutyrate in aging[J]. Smart Materials in Medicine, 2023, 4: 160-172.
[9]	WANG B L, WU J F, XIAO D, et al. 3-hydroxybutyrate in the brain: Biosynthesis, function, and disease therapy[J]. Brain‐X, 2023, 1(1): e6.
[10]	LIU S, YU J M, GAN Y C, et al. Biomimetic natural biomaterials for tissue engineering and regenerative medicine: new biosynthesis methods, recent advances, and emerging applications[J]. Military Medical Research, 2023, 10(1): 16.
[11]	XU T, HUANG X Y, DAO J W, et al. Synthetic biology for medical biomaterials[J]. Interdisciplinary Medicine, 2025, 3(4): e20240087.
[12]	ZHAO X H, PENG X L, GONG H L, et al. Osteogenic differentiation system based on biopolymer nanoparticles for stem cells in simulated microgravity[J]. Biomedical Materials, 2021, 16(4): 044102.
[13]	ZHAO X H, NIU Y N, MI C H, et al. Electrospinning nanofibers of microbial polyhydroxyalkanoates for applications in medical tissue engineering[J]. Journal of Polymer Science, 2021, 59(18): 1994-2013.
[14]	PENG X L, CHENG J S Y, GONG H L, et al. Advances in the design and development of SARS-CoV-2 vaccines[J]. Military Medical Research, 2021, 8(1): 67.
[15]	FU S Y, DU X Y, ZHU M, et al. 3D printing of layered mesoporous bioactive glass/sodium alginate-sodium alginate scaffolds with controllable dual-drug release behaviors[J]. Biomedical Materials, 2019, 14(6): 065011.
[16]	DU X Y, WEI D X, HUANG L, et al. 3D printing of mesoporous bioactive glass/silk fibroin composite scaffolds for bone tissue engineering[J]. Materials Science & Engineering C, Materials for Biological Applications, 2019, 103: 109731.
[17]	CHE X M, WEI D X, CHEN G Q. Superhydrophobic polyhydroxyalkanoates: preparation and applications[J]. Biomacromolecules, 2019, 20(2): 618-624.
[18]	WEI D X, DAO J W, CHEN G Q. A micro-ark for cells: highly open porous polyhydroxyalkanoate microspheres as injectable scaffolds for tissue regeneration[J]. Advanced Materials, 2018, 30(31): 1802273.
[19]	QIN Q, LING C, ZHAO Y Q, et al. CRISPR/Cas9 editing genome of extremophile Halomonas spp[J]. Metabolic Engineering, 2018, 47: 219-229.
[20]	JUNG H R, YANG S Y, MOON Y M, et al. Construction of efficient platform Escherichia coli strains for polyhydroxyalkanoate production by engineering branched pathway[J]. Polymers, 2019, 11(3): 509.
[21]	TAO W, LV L, CHEN G Q. Engineering Halomonas species TD01 for enhanced polyhydroxyalkanoates synthesis via CRISPRi[J]. Microbial Cell Factories, 2017, 16(1): 48.
[22]	LV L, REN Y L, CHEN J C, et al. Application of CRISPRi for prokaryotic metabolic engineering involving multiple genes, a case study: Controllable P(3HB-co-4HB) biosynthesis[J]. Metabolic Engineering, 2015, 29: 160-168.
[23]	WANG X P, LIN L, DONG J D, et al. Simultaneous improvements of Pseudomonas cell growth and polyhydroxyalkanoate production from a lignin derivative for lignin-consolidated bioprocessing[J]. Applied and Environmental Microbiology, 2018, 84(18): e01469-18.
[24]	RIGOUIN C, LAJUS S, OCANDO C, et al. Production and characterization of two medium-chain-length polydroxyalkanoates by engineered strains of Yarrowia lipolytica [J]. Microbial Cell Factories, 2019, 18(1): 99.
[25]	ZHANG X, LIN Y N, WU Q, et al. Synthetic biology and genome-editing tools for improving PHA metabolic engineering[J]. Trends in Biotechnology, 2020, 38(7): 689-700.
[26]	LIU C L, WANG X T, YANG H Y, et al. Biodegradable polyhydroxyalkanoates production from wheat straw by recombinant Halomonas elongata A1[J]. International Journal of Biological Macromolecules, 2021, 187: 675-682.
[27]	SHEN R, YIN J, YE J W, et al. Promoter engineering for enhanced P(3HB-co-4HB) production by Halomonas bluephagenesis [J]. ACS Synthetic Biology, 2018, 7(8): 1897-1906.
[28]	KIM E J, KIM K J. Crystal structure and biochemical characterization of PhaA from Ralstonia eutropha, a polyhydroxyalkanoate-producing bacterium[J]. Biochemical and Biophysical Research Communications, 2014, 452(1): 124-129.
[29]	KIM E J, SON H F, KIM S, et al. Crystal structure and biochemical characterization of beta-keto thiolase B from polyhydroxyalkanoate-producing bacterium Ralstonia eutropha H16[J]. Biochemical and Biophysical Research Communications, 2014, 444(3): 365-369.
[30]	KIM J, CHANG J H, KIM E J, et al. Crystal structure of (R)-3-hydroxybutyryl-CoA dehydrogenase PhaB from Ralstonia eutropha [J]. Biochemical and Biophysical Research Communications, 2014, 443(3): 783-788.
[31]	WITTENBORN E C, JOST M, WEI Y F, et al. Structure of the catalytic domain of the class I polyhydroxybutyrate synthase from Cupriavidus necator [J]. Journal of Biological Chemistry, 2016, 291(48): 25264-25277.
[32]	YE J W, HU D K, YIN J, et al. Stimulus response-based fine-tuning of polyhydroxyalkanoate pathway in Halomonas [J]. Metabolic Engineering, 2020, 57: 85-95.
[33]	ZHENG S, ZHANG Z H, JIANG P, et al. A self-stimulating system based on a polyhydroxyalkanoates coupled induction mechanism and its applications for Halomonas [J]. Chemical Engineering Journal, 2024, 489: 151413.
[34]	WANG X, HAN J N, ZHANG X, et al. Reversible thermal regulation for bifunctional dynamic control of gene expression in Escherichia coli [J]. Nature Communications, 2021, 12: 1411.
[35]	REN K, ZHAO Y Q, CHEN G Q, et al. Construction of a Stable Expression System Based on the Endogenous hbpB/hbpC Toxin–Antitoxin System of Halomonas bluephagenesis [J]. ACS Synthetic Biology, 2024, 13(1): 61-67.
[36]	MA Y Y, YE J W, LIN Y N, et al. Flux optimization using multiple promoters in Halomonas bluephagenesis as a model chassis of the next generation industrial biotechnology[J]. Metabolic Engineering, 2024, 81: 249-261.
[37]	LI Z J, SHI Z Y, JIAN J, et al. Production of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) from unrelated carbon sources by metabolically engineered Escherichia coli [J]. Metabolic Engineering, 2010, 12(4): 352-359.
[38]	FU X Z, TAN D, AIBAIDULA G, et al. Development of Halomonas TD01 as a host for open production of chemicals[J]. Metabolic Engineering, 2014, 23: 78-91.
[39]	CHEN G Q, JIANG X R. Next generation industrial biotechnology based on extremophilic bacteria[J]. Current Opinion in Biotechnology, 2018, 50: 94-100.
[40]	DYE N A, PINCUS Z, FISHER I C, et al. Mutations in the nucleotide binding pocket of MreB can alter cell curvature and polar morphology in Caulobacter [J]. Molecular Microbiology, 2011, 81(2): 368-394.
[41]	JIANG X R, YAO Z H, CHEN G Q. Controlling cell volume for efficient PHB production by Halomonas [J]. Metabolic Engineering, 2017, 44: 30-37.
[42]	WU H, FAN Z Y, JIANG X R, et al. Enhanced production of polyhydroxybutyrate by multiple dividing E. coli [J]. Microbial Cell Factories, 2016, 15(1): 128.
[43]	WU H, CHEN J C, CHEN G Q. Engineering the growth pattern and cell morphology for enhanced PHB production by Escherichia coli [J]. Applied Microbiology and Biotechnology, 2016, 100(23): 9907-9916.
[44]	YIN J, CHEN J C, WU Q, et al. Halophiles, coming stars for industrial biotechnology[J]. Biotechnology Advances, 2015, 33(7): 1433-1442.
[45]	PAULDINE JR. Assessment of Purification Methods for the Removal of Endotoxins from Polymers Generated by E . coli[D]. Syracuse : State University of New York College of Environmental Science and Forestry, 2016.
[46]	RAN G Q, TAN D, ZHAO J P, et al. Functionalized polyhydroxyalkanoate nano-beads as a stable biocatalyst for cost-effective production of the rare sugar D-allulose[J]. Bioresource Technology, 2019, 289: 121673.
[47]	CHEN X B, YU L P, QIAO G Q, et al. Reprogramming Halomonas for industrial production of chemicals[J]. Journal of Industrial Microbiology & Biotechnology, 2018, 45(7): 545-554.
[48]	CHEN G Q, HAJNAL I, WU H, et al. Engineering biosynthesis mechanisms for diversifying polyhydroxyalkanoates[J]. Trends in Biotechnology, 2015, 33(10): 565-574.
[49]	XU N, WEI L, LIU J. Recent advances in the applications of promoter engineering for the optimization of metabolite biosynthesis[J]. World Journal of Microbiology and Biotechnology, 2019, 35(2): 33.
[50]	LI T, YE J W, SHEN R, et al. Semirational approach for ultrahigh poly(3-hydroxybutyrate) accumulation in Escherichia coli by combining one-step library construction and high-throughput screening[J]. ACS Synthetic Biology, 2016, 5(11): 1308-1317.
[51]	SALIS H M, MIRSKY E A, VOIGT C A. Automated design of synthetic ribosome binding sites to control protein expression[J]. Nature Biotechnology, 2009, 27(10): 946-950.
[52]	RAZA Z ALI, ABID S, BANAT I M. Polyhydroxyalkanoates: Characteristics, production, recent developments and applications[J]. International Biodeterioration & Biodegradation, 2018, 126: 45-56.
[53]	STEINBÜCHEL A, LÜTKE-EVERSLOH T. Metabolic engineering and pathway construction for biotechnological production of relevant polyhydroxyalkanoates in microorganisms[J]. Biochemical Engineering Journal, 2003, 16(2): 81-96.
[54]	WANG Z Y, QIN Q, ZHENG Y F, et al. Engineering the permeability of Halomonas bluephagenesis enhanced its chassis properties[J]. Metabolic Engineering, 2021, 67: 53-66.
[55]	TAN D, WU Q, CHEN J C, et al. Engineering Halomonas TD01 for the low-cost production of polyhydroxyalkanoates[J]. Metabolic Engineering, 2014, 26: 34-47.
[56]	WANG Y, WU H, JIANG X R, et al. Engineering Escherichia coli for enhanced production of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in larger cellular space[J]. Metabolic Engineering, 2014, 25: 183-193.
[57]	YUAN S S, SHEN Y, LI Z B. Injectable cell- and growth factor-free poly(4-hydroxybutyrate) (P4HB) microspheres with open porous structures and great efficiency of promoting bone regeneration[J]. ACS Applied Bio Materials, 2021, 4(5): 4432-4440.
[58]	RAHMAN M, PENG X L, ZHAO X H, et al. 3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteoinduction of stem cells for bone tissue regeneration[J]. Bioactive Materials, 2021, 6(11): 4083-4095.
[59]	HUANG X Y, ZHOU X X, YANG H, et al. Directed osteogenic differentiation of human bone marrow mesenchymal stem cells via sustained release of BMP4 from PBVHx-based nanoparticles[J]. International Journal of Biological Macromolecules, 2024, 265(Pt 1): 130649.
[60]	REYHANEH GHAVAMI L, BIAZAR E, TALEGHANI A S, et al. Design of curcumin-loaded electrospun polyhydroxybutyrate mat as a wound healing material[J]. Nano Biomedicine and Engineering, 2020, 12(1): 14-20.
[61]	LI J, CHEN J N, PENG Z X, et al. Multifunctional electrospinning polyhydroxyalkanoate fibrous scaffolds with antibacterial and angiogenesis effects for accelerating wound healing[J]. ACS Applied Materials & Interfaces, 2023, 15(1): 364-377.
[62]	DING Y W, LI Y, ZHANG Z W, et al. Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment[J]. Bioactive Materials, 2024, 38: 95-108.
[63]	GAO J, HUANG Z Z, GUO H W, et al. Effect of wall structures on mechanical properties of small caliber PHBHHx vascular grafts[J]. Fibers and Polymers, 2019, 20(11): 2261-2267.
[64]	JIAN Y H, ZHU Y F. Poly 3-hydroxybutyrate 4-hydroxybutyrate (P34HB) as a potential polymer for drug-eluting coatings on metal coronary stents[J]. Polymers, 2022, 14(5): 994.
[65]	ANTONOVA L V, SEVOSTYANOVA V V, MIRONOV A V, et al. In situ vascular tissue remodeling using biodegradable tubular scaffolds with incorporated growth factors and chemoattractant molecules[J]. Complex Issues of Cardiovascular Diseases, 2018, 7(2): 25-36.
[66]	WANG D F, WANG C, BI Z J, et al. Expanded polytetrafluoroethylene/poly(3-hydroxybutyrate) (ePTFE/PHB) triboelectric nanogenerators and their potential applications as self-powered and sensing vascular grafts[J]. Chemical Engineering Journal, 2023, 455: 140494.
[67]	CHEN F F, LIU X Y, GE X Y, et al. Porous polydroxyalkanoates (PHA) scaffolds with antibacterial property for oral soft tissue regeneration[J]. Chemical Engineering Journal, 2023, 451: 138899.
[68]	PHUEGYOD S, PRAMUAL S, WATTANAVICHEAN N, et al. Microbial poly(hydroxybutyrate-co-hydroxyvalerate) scaffold for periodontal tissue engineering[J]. Polymers, 2023, 15(4): 855.
[69]	HU J, WANG M, XIAO X Y, et al. A novel long-acting azathioprine polyhydroxyalkanoate nanoparticle enhances treatment efficacy for systemic lupus erythematosus with reduced side effects[J]. Nanoscale, 2020, 12(19): 10799-10808.
[70]	PARLANE N A, WEDLOCK D N, BUDDLE B M, et al. Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents[J]. Applied and Environmental Microbiology, 2009, 75(24): 7739-7744.
[71]	WEI D X, CAI D F, TAN Y G, et al. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate)-based microspheres as a sustained platform for Huperzine A delivery for Alzheimer's disease therapy[J]. International Journal of Biological Macromolecules, 2024, 282(Pt 1): 136582.
[72]	MARINO G, ROSSO F, CAFIERO G, et al. Beta-tricalcium phosphate 3D scaffold promote alone osteogenic differentiation of human adipose stem cells: in vitro study[J]. Journal of Materials Science Materials in Medicine, 2010, 21(1): 353-363.
[73]	IM G I, KIM H J, LEE J H. Chondrogenesis of adipose stem cells in a porous PLGA scaffold impregnated with plasmid DNA containing SOX trio (SOX-5, -6 and-9) genes[J]. Biomaterials, 2011, 32(19): 4385-4392.
[74]	WEI D X, DAO J W, LIU H W, et al. Suspended polyhydroxyalkanoate microspheres as 3D carriers for mammalian cell growth[J]. Artificial Cells, Nanomedicine, and Biotechnology, 2018, 46(sup2): 473-483.
[75]	FU N, MENG Z S, JIAO T J, et al. P34HB electrospun fibres promote bone regeneration in vivo [J]. Cell Proliferation, 2019, 52(3): e12601.
[76]	MEISCHEL M, EICHLER J, MARTINELLI E, et al. Adhesive strength of bone-implant interfaces and in-vivo degradation of PHB composites for load-bearing applications[J]. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 53: 104-118.
[77]	BERND H E, KUNZE C, FREIER T, et al. Poly(3-hydroxybutyrate) (PHB) patches for covering anterior skull base defects-an animal study with minipigs[J]. Acta Oto-Laryngologica, 2009, 129(9): 1010-1017.
[78]	ZHANG X, LI J, CHEN J, et al. Enhanced bone regeneration via PHA scaffolds coated with polydopamine-captured BMP2[J]. Journal of Materials Chemistry B, 2022, 10(32): 6214-6227.
[79]	ZHANG H N, MIGNECO F, LIN C Y, et al. Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells[J]. Tissue Engineering Part A, 2010, 16(11): 3441-3448.
[80]	BARBOSA J L, DE MELO M I A, SILVA CUNHA P DA, et al. Development of a membrane and a bilayer of chitosan, gelatin, and polyhydroxybutyrate to be used as wound dressing for the regeneration of rat excisional wounds[J]. Journal of Biomedical Materials Research Part A, 2024, 112(1): 82-98.
[81]	DAISY E R A C, RAJENDRAN N K, HOURELD N N, et al. Curcumin and Gymnema sylvestre extract loaded graphene oxide-polyhydroxybutyrate-sodium alginate composite for diabetic wound regeneration[J]. Reactive and Functional Polymers, 2020, 154: 104671.
[82]	SANHUEZA C, HERMOSILLA J, BUGALLO-CASAL A, et al. One-step electrospun scaffold of dual-sized gelatin/poly-3-hydroxybutyrate nano/microfibers for skin regeneration in diabetic wound[J]. Materials Science & Engineering C, Materials for Biological Applications, 2021, 119: 111602.
[83]	PESCHEL G, DAHSE H M, KONRAD A, et al. Growth of keratinocytes on porous films of poly(3-hydroxybutyrate) and poly(4-hydroxybutyrate) blended with hyaluronic acid and chitosan[J]. Journal of Biomedical Materials Research Part A, 2008, 85A(4): 1072-1081.
[84]	RIVERA-BRISO A L, AACHMANN F L, MORENO-MANZANO V, et al. Graphene oxide nanosheets versus carbon nanofibers: Enhancement of physical and biological properties of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) films for biomedical applications[J]. International Journal of Biological Macromolecules, 2020, 143: 1000-1008.
[85]	JI Y, LI X T, CHEN G Q. Interactions between a poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) terpolyester and human keratinocytes[J]. Biomaterials, 2008, 29(28): 3807-3814.
[86]	HE Y, HU Z W, REN M D, et al. Evaluation of PHBHHx and PHBV/PLA fibers used as medical sutures[J]. Journal of Materials Science: Materials in Medicine, 2014, 25(2): 561-571.
[87]	GUO W T, WANG X C, YANG C Y, et al. Microfluidic 3D printing polyhydroxyalkanoates-based bionic skin for wound healing[J]. Materials Futures, 2022, 1(1): 015401.
[88]	BASNETT P, MATHARU R K, TAYLOR C S, et al. Harnessing polyhydroxyalkanoates and pressurized gyration for hard and soft tissue engineering[J]. ACS Applied Materials & Interfaces, 2021, 13(28): 32624-32639.
[89]	ANTONOVA L V, KRIVKINA E O, SEVOSTIANOVA V V, et al. Tissue-engineered carotid artery interposition grafts demonstrate high primary patency and promote vascular tissue regeneration in the ovine model[J]. Polymers, 2021, 13(16): 2637.
[90]	ANTONOVA L V, MIRONOV A V, YUZHALIN A E, et al. A brief report on an implantation of small-caliber biodegradable vascular grafts in a carotid artery of the sheep[J]. Pharmaceuticals, 2020, 13(5): 101.

PHA	Tg (℃)	T_m (℃)	Rm (MPa)	Ym (MPa)	Eb (%)	Xc (%)	WCA (℃)	Ta (℃)
Commercialized
PHB	-1.20-4.0	162.0-179.0	18.5-43.0	108.0-554.0	4.5-5.0	60.0-80.0	89.0	212.0
P4HB	-51.0 to-48.0	53.0-60.0	50.0	70.0-670.0	1000.0	ND	74.0-80.0	308.5
PHBV	-1.7-5.0	120.0-170.0	2.7	65.8	30.0-123.0	58.1-65.7	69.6-80.8	279.6
PHBHHx	-1.8-4.0	52.0-151.0	4.1	130.4	107.7-270.0	25.0-43.0	85.2-87.2	220.0
P34HB	-4.2-7.4	50.0-166.0	23.1-25.8	902.0	3.7-13.0	80.0-90.3	60.2-96.1	239.6
PHBVHHx	-2.6 to -1.2	69.6-152.1	5.1	284.6	276.9-739.7	ND	90.3-90.6	255.5
Uncommercialized
PHV	-15.0	119.0	31.0	ND	ND	ND	ND	258.0
PHHx	-28.2	ND	ND	ND	ND	ND	ND	211.6
PHP	-20.0	77.0	27.0	300.0	ND	ND	ND	ND
PHO	-35.4	52.8-61.0	6.0-10.0	33.0-41.0	ND	36.7	ND	256.2
PHBHP	-3.1 to -2.1	119.8-162.8	ND	ND	ND	ND	ND	150.0
PHBHV4HB	-51.0 to -10.0	55.0-131.0	12.8-14.3	30.0-140.0	316.0-937.0	ND	ND	ND

PHA	Tg (℃)	T_m (℃)	Rm (MPa)	Ym (MPa)	Eb (%)	Xc (%)	WCA (℃)	Ta (℃)
Commercialized
PHB	-1.20-4.0	162.0-179.0	18.5-43.0	108.0-554.0	4.5-5.0	60.0-80.0	89.0	212.0
P4HB	-51.0 to-48.0	53.0-60.0	50.0	70.0-670.0	1000.0	ND	74.0-80.0	308.5
PHBV	-1.7-5.0	120.0-170.0	2.7	65.8	30.0-123.0	58.1-65.7	69.6-80.8	279.6
PHBHHx	-1.8-4.0	52.0-151.0	4.1	130.4	107.7-270.0	25.0-43.0	85.2-87.2	220.0
P34HB	-4.2-7.4	50.0-166.0	23.1-25.8	902.0	3.7-13.0	80.0-90.3	60.2-96.1	239.6
PHBVHHx	-2.6 to -1.2	69.6-152.1	5.1	284.6	276.9-739.7	ND	90.3-90.6	255.5
Uncommercialized
PHV	-15.0	119.0	31.0	ND	ND	ND	ND	258.0
PHHx	-28.2	ND	ND	ND	ND	ND	ND	211.6
PHP	-20.0	77.0	27.0	300.0	ND	ND	ND	ND
PHO	-35.4	52.8-61.0	6.0-10.0	33.0-41.0	ND	36.7	ND	256.2
PHBHP	-3.1 to -2.1	119.8-162.8	ND	ND	ND	ND	ND	150.0
PHBHV4HB	-51.0 to -10.0	55.0-131.0	12.8-14.3	30.0-140.0	316.0-937.0	ND	ND	ND

Technology Category	Tools/Strategies	Application Case	Effects/Advantages
CRISPR/Cas Tools	CRISPR/Cas9	prpC gene deletion in Halomonas bluephagenesis	16-fold increase in 3HV proportion in PHBV^[19]
	CRISPR/Cas9	Deletion of byproduct genes (pflB etc.) in E. coli	Enhanced cell growth and PHA yield^[20]
	CRISPRi	Suppression of propionate consumption pathway	Improved substrate to PHB conversion efficiency^[21]
	CRISPRi	Inhibition of 4HB competing pathways	Controlled 3HB/4HB monomer ratio^[22]
Promoter Engineering	Inducible promoter	Activation of PHA biosynthesis genes in Pseudomonas putida	Significantly improved PHA synthesis efficiency^[23]
	Constitutive promoter	phaC continuous expression in Yarrowia lipolytica	Promoted fatty acid copolymer synthesis^[24]
	Dual promoter	The dual promoters (T7 and Pporin) act in concert on the phaCAB operon in Halomonas elongata.	27.5% increase in PHB production^[25-26]
	Promoter library	High-efficiency promoter screening for 4HB transferase gene	Achieved 80wt% P34HB accumulation^[27]
RBS Optimization	RBS library design (computational tools + OLMA)	Optimization of PHA synthase gene translation in Cupriavidus necator	PHB production increased from 0% to 92% of cell dry weight^[28-30]
RBS Optimization	RBS library optimization	PHB production enhancement in E. coli	Yield improvement from 0% to 92% of cell dry weight^[28-31]
Pathway Fine-tuning	Dynamic range control system	Regulation of 4HB synthesis genes in H. bluephagenesis	P34HB production >36 g/L in 7 L culture (16 mol% 4HB content) ^[32]
	Protein autoactivation system (PhaR/PhaP1)	Single/dual-copy autoactivation system in H. bluephagenesis	Achieved 97.4 g/L cell density (76.3% PHA of dry weight)^[33]
	Temperature sensitive bioswitch	PHA monomer ratio control in E. coli	Produced diblock/random copolymers with tunable structures^[34]
	Toxin-antitoxin stabilization (hbpB/hbpC)	H. bluephagenesis continuous subculture	Maintained stability for 7 days without antibiotics^[35]
	Multi-inducible system (10 signals)	Coordinated regulation of chromoproteins, lycopene and PHB in H. bluephagenesis	Enhanced cell proliferation and product yield^[36]
Metabolic Engineering	Gene knockout (FadA/FadB/GabD)	Attenuation of β-oxidation cycle, prevention of SSA loss	Significantly increased PHA accumulation^[37]
Metabolic Engineering	Cofactor optimization (Udh overexpression)	Enhanced NADH/NADPH supply	Improved PHA synthesis efficiency^[37-38]
Morphological Engineering	Division ring disruption (FtsZ-GFP)	Cell elongation in Halomonas campaniensis LS21	PHB content increased from 56wt% to 78wt%^[39]
	Cytoskeleton regulation (mreB knockout + conditional complementation)	Cell rounding/volume increase in Halomonas campaniensis LS21	Achieved 5 μm cell diameter with significantly improved PHB production^[40-41]
	Multidivision induction (ΔminCD + ftsQ/Z/mreB overexpression)	Synergistic multidivision and elongation in E. coli JM109	PHB accumulation increased by >80%^[42-43]
Chromosomal Integration & Membrane Engineering	Chromosomal integration	udhA gene integration in Halomonas TD08 (NADPH-dependent transhydrogenase)	PHB increased from 87% to 92% CDW, glucose conversion efficiency from 30% to 42% ^[44]
Chromosomal Integration & Membrane Engineering	OM-deficient strains	Low-endotoxin strains (e.g., ClearColi™ BL21(DE3)) for PHA production	Reduced endotoxin content, simplified purification, improved biocompatibility ^[45-46]

Technology Category	Tools/Strategies	Application Case	Effects/Advantages
CRISPR/Cas Tools	CRISPR/Cas9	prpC gene deletion in Halomonas bluephagenesis	16-fold increase in 3HV proportion in PHBV^[19]
	CRISPR/Cas9	Deletion of byproduct genes (pflB etc.) in E. coli	Enhanced cell growth and PHA yield^[20]
	CRISPRi	Suppression of propionate consumption pathway	Improved substrate to PHB conversion efficiency^[21]
	CRISPRi	Inhibition of 4HB competing pathways	Controlled 3HB/4HB monomer ratio^[22]
Promoter Engineering	Inducible promoter	Activation of PHA biosynthesis genes in Pseudomonas putida	Significantly improved PHA synthesis efficiency^[23]
	Constitutive promoter	phaC continuous expression in Yarrowia lipolytica	Promoted fatty acid copolymer synthesis^[24]
	Dual promoter	The dual promoters (T7 and Pporin) act in concert on the phaCAB operon in Halomonas elongata.	27.5% increase in PHB production^[25-26]
	Promoter library	High-efficiency promoter screening for 4HB transferase gene	Achieved 80wt% P34HB accumulation^[27]
RBS Optimization	RBS library design (computational tools + OLMA)	Optimization of PHA synthase gene translation in Cupriavidus necator	PHB production increased from 0% to 92% of cell dry weight^[28-30]
RBS Optimization	RBS library optimization	PHB production enhancement in E. coli	Yield improvement from 0% to 92% of cell dry weight^[28-31]
Pathway Fine-tuning	Dynamic range control system	Regulation of 4HB synthesis genes in H. bluephagenesis	P34HB production >36 g/L in 7 L culture (16 mol% 4HB content) ^[32]
	Protein autoactivation system (PhaR/PhaP1)	Single/dual-copy autoactivation system in H. bluephagenesis	Achieved 97.4 g/L cell density (76.3% PHA of dry weight)^[33]
	Temperature sensitive bioswitch	PHA monomer ratio control in E. coli	Produced diblock/random copolymers with tunable structures^[34]
	Toxin-antitoxin stabilization (hbpB/hbpC)	H. bluephagenesis continuous subculture	Maintained stability for 7 days without antibiotics^[35]
	Multi-inducible system (10 signals)	Coordinated regulation of chromoproteins, lycopene and PHB in H. bluephagenesis	Enhanced cell proliferation and product yield^[36]
Metabolic Engineering	Gene knockout (FadA/FadB/GabD)	Attenuation of β-oxidation cycle, prevention of SSA loss	Significantly increased PHA accumulation^[37]
Metabolic Engineering	Cofactor optimization (Udh overexpression)	Enhanced NADH/NADPH supply	Improved PHA synthesis efficiency^[37-38]
Morphological Engineering	Division ring disruption (FtsZ-GFP)	Cell elongation in Halomonas campaniensis LS21	PHB content increased from 56wt% to 78wt%^[39]
	Cytoskeleton regulation (mreB knockout + conditional complementation)	Cell rounding/volume increase in Halomonas campaniensis LS21	Achieved 5 μm cell diameter with significantly improved PHB production^[40-41]
	Multidivision induction (ΔminCD + ftsQ/Z/mreB overexpression)	Synergistic multidivision and elongation in E. coli JM109	PHB accumulation increased by >80%^[42-43]
Chromosomal Integration & Membrane Engineering	Chromosomal integration	udhA gene integration in Halomonas TD08 (NADPH-dependent transhydrogenase)	PHB increased from 87% to 92% CDW, glucose conversion efficiency from 30% to 42% ^[44]
Chromosomal Integration & Membrane Engineering	OM-deficient strains	Low-endotoxin strains (e.g., ClearColi™ BL21(DE3)) for PHA production	Reduced endotoxin content, simplified purification, improved biocompatibility ^[45-46]

Application	PHA Type	Key Findings/ Innovations	References
Bone Tissue Repair & Aerospace	PHBVHHx	- PHBVHHx OPM enable minimally invasive injection and bone regeneration.support bone health in microgravity.	[18]
	P4HB	- P4HB-OPM promotes bone regeneration without cells/growth factors.	[57]
	P34HB	- PHA nanoparticles (P34HB, PHBVHx) loaded with BMPs	[12,58-59]
Skin Tissue Repair & Medical Cosmetology	PHB, PHBV	- PHB/PHBV has the properties of promoting skin repair, loading drugs or cells, and mimicking the extracellular matrix.	[60]
	P34HB	- Electrospun P34HB scaffolds accelerate wound healing with antibacterial/angiogenic properties.	[61]
	PHBVHHx	- PHBVHHx nanoparticles enhance microneedle delivery of hair-growth drugs (e.g., ritlecitinib) for androgenetic alopecia.	[62]
Cardiovascular Tissue Engineering	PHBHHx	- PHBHHx patches for vascular grafts.	[63]
	P34HB	- P34HB coatings for coronary stents.	[64]
	PHBV	- PHBV/PCL electrospun scaffolds with VEGF improve vascular patency and regeneration.	[65]
	PHB	- The composite material of PHB and ePTFE is suitable for cardiovascular sensing.	[66]
Oral Soft Tissue Repair	P34HB	- P34HB/ZnO scaffolds with antibacterial properties promote gum regeneration.	[67]
Oral Soft Tissue Repair	PHBV	- P(HB-50HV) supports high proliferation of gingival fibroblasts.	[68]
Adjuvant Immune Regulation	PHBVHHx	- AZA-loaded PHBVHHx nanoparticles reduce toxicity and enhance efficacy in treating lupus.	[69]
Vaccines & Virus Mimetics	PHA-based particles	- PHA particles simulate viral structures to enhance antigen presentation (e.g., for TB/COVID-19).	[14]
Vaccines & Virus Mimetics	PHA-based particles	-Challenges include endotoxin contamination from E. coli.	[70]
Treatment of Alzheimer’s Disease	PHBVHHx	- PHBVHHx microspheres enable sustained release of huperzine A, reducing neurotoxicity.	[71]
Organoid Assistance	PHBVHHx	- Porous PHBVHHx microspheres support 3D cell growth and mimic extracellular matrix.	[72-74]

医用聚羟基脂肪酸酯（PHA）的生物合成策略及其在人类健康领域的新进展

Biosynthetic strategies of medical polyhydroxyalkanoate （PHA） and their new developments for human health

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 90

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋开南, 张礼文, 王超, 田平芳, 李广悦, 潘国辉, 徐玉泉. 小分子生物农药及其生物合成研究进展[J]. 合成生物学, 2025, 6(5): 1203-1223.
[2]	于文文, 吕雪芹, 李兆丰, 刘龙. 植物合成生物学与母乳低聚糖生物制造[J]. 合成生物学, 2025, 6(5): 992-997.
[3]	颜钊涛, 周鹏飞, 汪阳忠, 张鑫, 谢雯燕, 田晨菲, 王勇. 植物合成生物学：植物细胞大规模培养的新机遇[J]. 合成生物学, 2025, 6(5): 1107-1125.
[4]	孙扬, 陈立超, 石艳云, 王珂, 吕丹丹, 徐秀美, 张立新. 作物光合作用合成生物学的策略与展望[J]. 合成生物学, 2025, 6(5): 1025-1040.
[5]	赵欣雨, 盛琦, 刘开放, 刘佳, 刘立明. 天冬氨酸族饲用氨基酸微生物细胞工厂的创制[J]. 合成生物学, 2025, 6(5): 1184-1202.
[6]	何杨昱, 杨凯, 王玮琳, 黄茜, 丘梓樱, 宋涛, 何流赏, 姚金鑫, 甘露, 何玉池. 国际基因工程机器大赛中植物合成生物学主题的设计与实践[J]. 合成生物学, 2025, 6(5): 1243-1254.
[7]	张学博, 朱成姝, 陈睿雲, 金庆姿, 刘晓, 熊燕, 陈大明. 农业合成生物学：政策规划与产业发展协同推进[J]. 合成生物学, 2025, 6(5): 1224-1242.
[8]	刘婕, 郜钰, 马永硕, 尚轶. 合成生物学在农业中的进展及挑战[J]. 合成生物学, 2025, 6(5): 998-1024.
[9]	郑雷, 郑棋腾, 张天骄, 段鲲, 张瑞福. 构建根际合成微生物菌群促进作物养分高效吸收利用[J]. 合成生物学, 2025, 6(5): 1058-1071.
[10]	李超, 张焕, 杨军, 王二涛. 固氮合成生物学研究进展[J]. 合成生物学, 2025, 6(5): 1041-1057.
[11]	魏家秀, 嵇佩云, 节庆雨, 黄秋燕, 叶浩, 戴俊彪. 植物人工染色体的构建与应用[J]. 合成生物学, 2025, 6(5): 1093-1106.
[12]	方馨仪, 孙丽超, 霍毅欣, 王颖, 岳海涛. 微生物合成高级醇的发展趋势与挑战[J]. 合成生物学, 2025, 6(4): 873-898.
[13]	朱欣悦, 陈恬恬, 邵恒煊, 唐曼玉, 华威, 程艳玲. 益生菌辅助防治恶性肿瘤的研究进展[J]. 合成生物学, 2025, 6(4): 899-919.
[14]	吴晓燕, 宋琪, 许睿, 丁陈君, 陈方, 郭勍, 张波. 合成生物学研发竞争态势对比分析[J]. 合成生物学, 2025, 6(4): 940-955.
[15]	张建康, 王文君, 郭洪菊, 白北辰, 张亚飞, 袁征, 李彦辉, 李航. 基于机器视觉的高通量微生物克隆挑选工作站研制及应用[J]. 合成生物学, 2025, 6(4): 956-971.